DSIP RESEARCH PEPTIDE

Discovery. Schoenenberger and Monnier worked from the cerebral venous blood of rabbits whose thalamus had been stimulated electrically. After sequencing the peptide they synthesised it alongside candidate fragments and related peptides and tested each by infusion into rabbit brain ventricles in a double-blind design; they reported that synthetic DSIP alone produced a significant, specific rise in delta and spindle EEG activity.¹

An unresolved origin. Nobody has isolated a gene, a confirmed precursor protein or a receptor for DSIP. A 2006 review titled it "a still unresolved riddle", judged the sleep-factor hypothesis "extremely poorly documented and still weak", and recalled that the reviewers' own early experiments saw slow-wave sleep effects with some synthetic analogues but not with DSIP itself.²

Stability. A 1987 study found DSIP broken down quickly when incubated in human or rat blood, whereas two analogues lasted longer.³ Any experiment that delivers the peptide systemically has to contend with that.

Human studies. The human data are few and inconsistent. In 1992 an independent Amsterdam group ran a double-blind study in 16 chronic insomniacs and saw only weak shifts in sleep efficiency and latency, possibly reflecting a change in the placebo group; they judged short-term DSIP unlikely to be of major value in that condition.⁴ A 2009 randomised study in 24 women under general anaesthesia recorded the reverse of what was expected: less delta activity and lighter anaesthesia on the bispectral index.⁵ ClinicalTrials.gov showed no registered DSIP or emideltide trials in September 2026.

Most of the literature is old, with over three-quarters of PubMed records on the peptide published before 2000. Our DSIP research article covers the full record, and what research peptides are explains how such compounds are made and labelled.

DSIP has no FDA approval; Drugs@FDA holds no product containing emideltide or DSIP.⁶ Australia's June 2026 Poisons Standard (F2026L00633) names neither DSIP nor emideltide.⁷ Whether a product counts as a therapeutic good depends on its supply and presentation; see our guide to Australian research peptide law. The research-grade DSIP sold here is not an approved medicine.

DSIP is also absent by name from the 2026 WADA Prohibited List. Absence is not permission: the List's examples are "including, but not limited to", and its S0 and S2 wording can capture substances it does not name. Anti-doping authorities decide whether that applies to a particular compound.⁸

DSIP starts with a tryptophan, a residue vulnerable to oxidation and to photo-oxidation, and the 1987 blood data show how fast enzymes can degrade it, so handling conditions matter. Keep the sealed vial dry, dark and at −20 °C or colder, bring it to room temperature in a desiccator before opening, and close it quickly, ideally under nitrogen or argon. Make solutions under clean conditions, divide them into single-use aliquots and freeze them, avoiding repeated freeze–thaw. Since a DSIP antiserum once recognised an unrelated brain peptide, confirm identity by mass spectrometry rather than immunoassay. More on storing lyophilised and reconstituted peptides and choosing a diluent for reconstitution.